NASDAQ:IDYA IDEAYA Biosciences Q2 2025 Earnings Report $37.36 -0.45 (-1.19%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$37.32 -0.05 (-0.12%) As of 10/2/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast IDEAYA Biosciences EPS ResultsActual EPS-$0.88Consensus EPS -$0.85Beat/MissMissed by -$0.03One Year Ago EPS-$0.68IDEAYA Biosciences Revenue ResultsActual Revenue$6.00 millionExpected Revenue$3.48 millionBeat/MissBeat by +$2.52 millionYoY Revenue GrowthNaNIDEAYA Biosciences Announcement DetailsQuarterQ2 2025Date8/5/2025TimeBefore Market OpensConference Call DateTuesday, August 5, 2025Conference Call Time6:00AM ETUpcoming EarningsIDEAYA Biosciences' Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, November 4, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) IDEAYA Biosciences Earnings HeadlinesIDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and DevelopmentSeptember 28, 2026 | prnewswire.comCan IDEAYA Biosciences (IDYA) Turn Uncharted Oncology Territory Into Commercial Gold?September 25, 2026 | insidermonkey.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.October 3 at 1:00 AM | Altimetry (Ad)IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)September 25, 2026 | prnewswire.comAnalyzing IDEAYA Biosciences (NASDAQ:IDYA) and Applied Dna Sciences (NASDAQ:BNBX)September 22, 2026 | americanbankingnews.comAnalysts Are Bullish on Top Healthcare Stocks: Xenon (XENE), IDEAYA Biosciences (IDYA)September 19, 2026 | theglobeandmail.comSee More IDEAYA Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like IDEAYA Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IDEAYA Biosciences and other key companies, straight to your email. Email Address About IDEAYA BiosciencesIDEAYA Biosciences (NASDAQ:IDYA) is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines for cancer. The company uses insights from tumor biology, cancer genetics and synthetic lethality to identify treatments designed to target specific molecular alterations in tumors. Its development pipeline includes darovasertib, an investigational protein kinase C inhibitor being studied primarily in genetically defined cancers, including GNAQ- or GNA11-mutated uveal melanoma. IDEAYA is also developing IDE397, an investigational MAT2A inhibitor intended for cancers with MTAP deletions, along with additional discovery and development programs targeting genetically selected tumors. Founded in 2015 and headquartered in South San Francisco, California, IDEAYA conducts research and clinical development activities through collaborations and clinical studies intended to serve patients in multiple international markets. The company’s programs remain investigational, and their safety and effectiveness have not been established for general use.View IDEAYA Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/28 - 10/02Time to Nibble on MCD Stock After it Enters Oversold Territory?McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCorning and AT&T's $3 Billion Fiber Deal Reveals Where AI Spending Goes Next Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
